SRNE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SRNE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the three months ended in Jun. 2023, Sorrento Therapeutics paid $2.19 Mil more to buy back shares than it received from issuing new shares. It received $91.64 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It spent $0.64 Mil on other financial activities. In all, Sorrento Therapeutics earned $88.81 Mil on financial activities for the three months ended in Jun. 2023.
The historical data trend for Sorrento Therapeutics's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sorrento Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Cash Flow from Financing | Get a 7-Day Free Trial | 326.00 | 78.89 | 174.24 | 181.33 | 311.72 |
Sorrento Therapeutics Quarterly Data | ||||||||||||||||||||
Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Cash Flow from Financing | Get a 7-Day Free Trial | 41.77 | 71.50 | 25.08 | 61.20 | 88.81 |
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Sorrento Therapeutics's Cash from Financing for the fiscal year that ended in Dec. 2022 is calculated as:
Cash Flow from Financing | (A: Dec. 2022 ) | ||||||||||
= | Issuance of Stock | + | Repurchase of Stock | + | Net Issuance of Debt | + | Net Issuance of Preferred Stock | + | Cash Flow for Dividends | + | Other Financing |
= | 402.334 | + | 0 | + | -92.24 | + | 0 | + | 0 | + | 1.624 |
= | 311.72 |
Sorrento Therapeutics's Cash from Financing for the quarter that ended in Jun. 2023 is:
Cash Flow from Financing | (Q: Jun. 2023 ) | ||||||||||
= | Issuance of Stock | + | Repurchase of Stock | + | Net Issuance of Debt | + | Net Issuance of Preferred Stock | + | Cash Flow for Dividends | + | Other Financing |
= | -2.185 | + | 0 | + | 91.636 | + | 0 | + | 0 | + | -0.638 |
= | 88.81 |
Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $246.59 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sorrento Therapeutics (OTCPK:SRNE) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Sorrento Therapeutics's issuance of stock for the three months ended in Jun. 2023 was $-2.19 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Sorrento Therapeutics's repurchase of stock for the three months ended in Jun. 2023 was $0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Sorrento Therapeutics's net issuance of debt for the three months ended in Jun. 2023 was $91.64 Mil. Sorrento Therapeutics received $91.64 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Sorrento Therapeutics's net issuance of preferred for the three months ended in Jun. 2023 was $0.00 Mil. Sorrento Therapeutics paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Sorrento Therapeutics's cash flow for dividends for the three months ended in Jun. 2023 was $0.00 Mil. Sorrento Therapeutics received $0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Sorrento Therapeutics's other financing for the three months ended in Jun. 2023 was $-0.64 Mil. Sorrento Therapeutics spent $0.64 Mil on other financial activities.
Thank you for viewing the detailed overview of Sorrento Therapeutics's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
Henry Ji | director, officer: See Remarks | 5370 RUETTE DE MER, SAN DIEGO CA 92130 |
Tammy Reilly | director | C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTORS PLACE, SAN DIEGO CA 92121 |
Kim Janda | director | 6042 CORNERSTONE CT. WEST, SUITE B, SAN DIEGO CA 92121 |
Elizabeth Czerepak | director | 201 ROUTE 17 NORTH, RUTHERFORD NJ 07070 |
Dorman Followwill | director | C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121 |
Najjam Asghar | officer: Chief Financial Officer | C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTORS PLACE, SAN DIEGO CA 92121 |
Robin L Smith | director | C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747 |
Edgar Lee | director | C/O OAKTREE CAPITAL MANAGEMENT, L.P., 333 SOUTH GRAND AVE, 28TH FLOOR, LOS ANGELES CA 90071 |
Jerome B Zeldis | officer: See Remarks | 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258 |
Jaisim Shah | director | C/O PROTINE DESIGN LAB, 37481 MARSTEN DR, NEWARK CA 94560 |
Yue Alexander Wu | director | C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121 |
David Lemus | director | C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121 |
Abg Management Ltd | 10 percent owner | UNIT 3002-04,30TH FLOOR,GLOUCESTER TOWER, THE LANDMARK,15 QUEEN'S ROAD CENTRAL, HONG KONG K3 000000 |
Jiong Shao | officer: Chief Financial Officer | SUITE 1003-1004, 10/F, ICBC TOWER, THREE GARDEN ROAD, CENTRAL, HONG KONG F4 000000 |
George K Ng | officer: See Remarks | C/O SORRENTO THERAPEUTICS, INC., 6042 CORNERSTONE COURT WEST, SUITE B, SAN DIEGO CA 92121 |
From GuruFocus
By sperokesalga sperokesalga • 02-13-2023
By PRNewswire PRNewswire • 02-14-2023
By GlobeNewswire GlobeNewswire • 02-19-2023
By Value_Insider Value_Insider • 12-05-2022
By Value_Insider Value_Insider • 11-29-2022
By PRNewswire PRNewswire • 03-29-2023
By sperokesalga sperokesalga • 06-13-2023
By Value_Insider Value_Insider • 12-06-2022
By PRNewswire PRNewswire • 02-22-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.